DK0682026T3 - Stabil krystallinsk (6S)- og (6R)-tetrahydrofolsyre - Google Patents

Stabil krystallinsk (6S)- og (6R)-tetrahydrofolsyre

Info

Publication number
DK0682026T3
DK0682026T3 DK95106285T DK95106285T DK0682026T3 DK 0682026 T3 DK0682026 T3 DK 0682026T3 DK 95106285 T DK95106285 T DK 95106285T DK 95106285 T DK95106285 T DK 95106285T DK 0682026 T3 DK0682026 T3 DK 0682026T3
Authority
DK
Denmark
Prior art keywords
tetrahydrofolic acid
stable crystalline
crystalline
stable
tetrahydrofolic
Prior art date
Application number
DK95106285T
Other languages
English (en)
Other versions
DK0682026T4 (da
Inventor
Hans Rudolf Mueller
Martin Ulmann
Rudolf Moser
Thomas Ammann
Original Assignee
Eprova Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4210562&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0682026(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eprova Ag filed Critical Eprova Ag
Application granted granted Critical
Publication of DK0682026T3 publication Critical patent/DK0682026T3/da
Publication of DK0682026T4 publication Critical patent/DK0682026T4/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/02Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK95106285T 1994-05-09 1995-04-27 Stabil krystallinsk (6S)- og (6R)-tetrahydrofolsyre DK0682026T4 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH144294A CH686369A5 (de) 1994-05-09 1994-05-09 Stabile kristalline (6S)- und (6R)-Tetrahydrofolseure.

Publications (2)

Publication Number Publication Date
DK0682026T3 true DK0682026T3 (da) 2000-04-17
DK0682026T4 DK0682026T4 (da) 2003-02-24

Family

ID=4210562

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95106285T DK0682026T4 (da) 1994-05-09 1995-04-27 Stabil krystallinsk (6S)- og (6R)-tetrahydrofolsyre

Country Status (19)

Country Link
US (2) US6271374B1 (da)
EP (1) EP0682026B2 (da)
JP (2) JP3419585B2 (da)
KR (1) KR950032192A (da)
CN (1) CN1063444C (da)
AT (1) ATE188699T1 (da)
AU (1) AU704363B2 (da)
CA (1) CA2148671C (da)
CH (1) CH686369A5 (da)
DE (1) DE59507591D1 (da)
DK (1) DK0682026T4 (da)
ES (1) ES2144066T5 (da)
FI (1) FI120585B (da)
GR (1) GR3032984T3 (da)
HU (1) HUT71612A (da)
NO (1) NO313673B1 (da)
PT (1) PT682026E (da)
RU (1) RU2165422C2 (da)
ZA (1) ZA953673B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH689831A5 (de) * 1995-11-07 1999-12-15 Eprova Ag Stabile kristalline Tetrahydrofolsaeure-Salze.
CH693905A5 (de) 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
CH695217A5 (de) * 1999-07-14 2006-01-31 Merck Eprova Ag Verfahren zur Trennung optischer Isomeren von Tetrahydrofolsäureestersalzen und Tetrahydrofolsäure.
CH694251A5 (de) 1999-07-14 2004-10-15 Eprova Ag Herstellung von Tetrahydropterin und Derivaten.
ITMI20020132A1 (it) 2002-01-25 2003-07-25 Gmt Fine Chemicals Sa Processo per l'ottenimento dell'acido (6s)-5,6,7,8-tetraidrofolico
KR20070005550A (ko) 2003-11-17 2007-01-10 바이오마린 파머수티컬 인크. 대사 장애 치료를 위한 조성물 및 방법
KR20060051135A (ko) * 2004-09-15 2006-05-19 니프로 가부시키가이샤 안정화된 주사용 수용액 제재
EP1819340A2 (en) * 2004-12-08 2007-08-22 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
NZ598171A (en) 2009-07-10 2014-11-28 Linzy O Scott Iii Methods and compositions for treating thyroid-related medical conditions with reduced folates
AU2011215669B2 (en) * 2010-02-12 2015-06-04 HedoniaUSA, Inc. Compositions and methods for treating depression
JP5925381B2 (ja) * 2012-04-13 2016-05-25 ▲連雲▼港金康和信▲薬業▼有限公司Lianyungang Jinkang Hexin Pharmaceutical Co., Ltd. 化合物[4−(2−アミノ−10−メチル−4−オキソ−6,7,8,9−テトラヒドロ−4a,7−エピミノピリミド[4,5−b][1,4]ジアゼピン−5(4H)−イル)ベンゾイル]−グルタメート及びその製造
US9492421B1 (en) 2013-11-14 2016-11-15 Argent Development Group, Llc Nutritional supplements for treatment of iron deficiency anemia
US9629846B1 (en) 2013-11-14 2017-04-25 Argent Development Group, Llc Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women
WO2016185413A1 (en) 2015-05-20 2016-11-24 Nestec S.A. Modified release formulations
US10059710B2 (en) 2016-02-17 2018-08-28 Merck & Cie Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid
AU2017397463B2 (en) 2016-11-03 2022-01-06 HedoniaUSA, Inc. Compositions and methods for treating depression
RU2019134064A (ru) 2017-03-31 2021-04-30 Мерк Патент Гмбх Кристаллическая натриевая соль 5-метил-(6s)-тетрагидрофолиевой кислоты
CA3058287A1 (en) 2017-03-31 2018-10-04 Merck Patent Gmbh Crystalline sodium salt of 5-methyl-(6s)-tetrahydrofolic acid
EP4501315A1 (en) 2023-08-04 2025-02-05 Lesaffre et Compagnie Liquid formulations of folates

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS497416A (da) * 1972-05-12 1974-01-23
US4665176A (en) * 1984-10-23 1987-05-12 Mitsui Toatsu Chemicals, Incorporated Process for the preparation of 5,6,7,8-tetrahydrofolic acid
GB8621268D0 (en) * 1986-09-03 1986-10-08 Univ Strathclyde Separation of substances
CH673459A5 (da) * 1987-05-15 1990-03-15 Eprova Ag
DE3821875C1 (da) * 1988-06-29 1990-02-15 Eprova Ag, Forschungsinstitut, Schaffhausen, Ch
ATE139799T1 (de) * 1989-12-11 1996-07-15 American Cyanamid Co Verfahren zur herstellung von optisch reinen diastereoisomeren von tetrahydrofolatverbindungen
CH680731A5 (da) * 1990-04-12 1992-10-30 Sapec Fine Chemicals
CH681303A5 (da) * 1991-01-16 1993-02-26 Eprova Ag
CH683261A5 (it) * 1991-10-10 1994-02-15 Applied Pharma Res Procedimento per la preparazione dell'acido metiltetraidrofolico nella forma (6(R,S)(-))N-5 e separazione del diastereoisomero attivo (6(S)(-))N-5) sotto forma di sali.
US5198547A (en) * 1992-03-16 1993-03-30 South Alabama Medical Science Foundation, Usa Process for N5-formylating tetrahydropteridines
US5698693A (en) * 1992-11-16 1997-12-16 The United States Of America As Represented By The Department Of Health And Human Services Process of separating the diastereomers of (6R,6S) -5,6,7,8-tetrahydrofolic acid derivatives
CH686672A5 (de) * 1992-12-01 1996-05-31 Cerbios Pharma Sa Verfahren zur Herstellung von (6S)-5,6,7,8-Tetrahydrofolsaeure.
WO2001070922A1 (en) 2000-03-21 2001-09-27 Bbj Environmental Solutions Inc. Aqueous cleaning composition with controlled ph

Also Published As

Publication number Publication date
DK0682026T4 (da) 2003-02-24
ES2144066T5 (es) 2003-11-01
US6271374B1 (en) 2001-08-07
FI120585B (fi) 2009-12-15
AU704363B2 (en) 1999-04-22
RU2165422C2 (ru) 2001-04-20
KR950032192A (ko) 1995-12-20
CH686369A5 (de) 1996-03-15
PT682026E (pt) 2000-05-31
US6596721B2 (en) 2003-07-22
CN1063444C (zh) 2001-03-21
FI952198A0 (fi) 1995-05-08
CN1122337A (zh) 1996-05-15
DE59507591D1 (de) 2000-02-17
JP3419585B2 (ja) 2003-06-23
CA2148671C (en) 2000-08-15
CA2148671A1 (en) 1995-11-10
NO951796D0 (no) 1995-05-08
RU95107144A (ru) 1997-03-20
NO313673B1 (no) 2002-11-11
ZA953673B (en) 1996-01-12
US20010002398A1 (en) 2001-05-31
FI952198L (fi) 1995-11-10
AU1793195A (en) 1995-11-16
JP4898081B2 (ja) 2012-03-14
NO951796L (no) 1995-11-10
ATE188699T1 (de) 2000-01-15
HUT71612A (en) 1996-01-29
EP0682026B1 (de) 2000-01-12
JPH0841062A (ja) 1996-02-13
GR3032984T3 (en) 2000-07-31
JP2003201291A (ja) 2003-07-18
EP0682026A1 (de) 1995-11-15
ES2144066T3 (es) 2000-06-01
EP0682026B2 (de) 2003-02-05

Similar Documents

Publication Publication Date Title
DK0682026T4 (da) Stabil krystallinsk (6S)- og (6R)-tetrahydrofolsyre
GB8802792D0 (en) Distributed fet amplifier & bias voltage supply circuit therefor
AU6307586A (en) Quinoline derivatives
GB8827928D0 (en) Pyrimidine derivatives
AU2030988A (en) Pyrimidine derivatives
AU1631788A (en) Pyrimidine derivatives
AU1097988A (en) Alkylmelatonins
AU563849B2 (en) Imidazo(1,5-alpha)pyrimidine derivatives
AU2237788A (en) Partially saturated diazepine, pyrimidine and imidazoline derivatives
EP0317175A3 (en) Pyrimidine derivatives
AU8214987A (en) Triazine derivatives
PT640608E (pt) Intermediarios na sintese de cefalosporinas
GB8703254D0 (en) Lasers & amplifiers
GB8827462D0 (en) Pyrimidine derivatives
AU1174588A (en) Anticonvulsant agents
AU1032488A (en) Pyrimidine derivatives
IN172911B (da)
AU2700988A (en) N-hydroxy-5-phenyl-2-furancarboximidamides useful as cardiotonic agents
AU1738988A (en) Pyrimidine derivatives
PY0101566A (es) [7-(3-disustituidos amino)phenyl]pyrazolo [1,5-a] pyrimidines
EP0443238A3 (en) Precision switched current source
ZA918346B (en) Ergoline derivatives.
FI954340A0 (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 1,2,4-triazolo(1,5-a)-pyrimidinderivat
NO157309C (no) Armatur for lysroer e.l. stavformete lyskilder.
AU2693288A (en) Ethanolamine derivatives